M. Koh, T. Spivak-Kroizman, G. Powis
Oct 1, 2009
Citations
1
Influential Citations
25
Citations
Journal
Clinical Cancer Research
Abstract
The hypoxia-inducible transcription factor (HIF)-1α inhibitor KC7F2 described in this issue of Clinical Cancer Research is the newest addition to an emerging class of antitumor agents targeting the hypoxia response. Here, we discuss the proposed mechanism of action of KC7F2 and its potential strengths and limitations in comparison with other promising HIF-1α inhibitors. (Clin Cancer Res 2009;15(19):5945–6)